- Home
- WDH vs SABS Comparison
WDH vs SABS Comparison
Compare WDH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDH | SABS |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 344.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WDH | SABS |
|---|---|---|
| Price | $1.06 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | ★ 649.1K | 276.9K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.71 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $1.85 |
| 52 Week High | $2.07 | $5.15 |
Technical Indicators
Market Signals| Indicator | WDH | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 43.81 |
| Support Level | $0.97 | $3.38 |
| Resistance Level | $1.15 | $4.02 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 43.72 | 32.98 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.